Aging Clinical and Experimental Research

, Volume 14, Issue 4, pp 314–318 | Cite as

Rejuvenating health systems for aging communities

  • Fred Paccaud
Thematic Section


Nowadays, about the half of Swiss women die after their 84th birthday (1). This unprecedented proportion of the population reaching an old age, or even a very old age (25% of women die after 89 years, and 5% after 95 years) is a novel aspect of human demographics, and represents the very last stage of the epidemiological transition, a term coined to describe the transformation of the prevailing health burden in the population, shifting from infectious and communicable pathologies to chronic and degenerative diseases. In developed countries, this epidemiological transition has been well documented during the last century (2; worldwide, a similar transition is taking place, with some countries still at mid (3) or early stages of transition (4). A striking aspect of the current transition is its speed. In India, the mean duration of life since 1947 has increased from 32 to 62 years. As a result, India, like many other developing countries, is facing a double burden of disease, i.e., an upsurge of degenerative diseases while the burden from the old agenda (i.e., malaria, tuberculosis) still reaches devastating proportions in the population. This double burden is certainly a crucial problem in developing countries, and probably is the most important health challenge for the coming century. A similar accelerated pace of change is observed with the decline of mortality at old age. Worldwide, the current estimate of centenarians is 100000, i.e., ten time more centenarians than the number estimated in 1960 (5). The downward trend in mortality, which is steeper with increasing age (6), is now the leading factor to increase the life expectancy in developed countries. In the United Kingdom, life expectancy increased by 2.5 years between 1971 and 1991; this is equivalent to the increase observed between 1851 and 1961 (7). This accelerated increase will influence public health in two different ways. The first will be the absolute increase in the number of older persons, with a corresponding increase in degenerative diseases. A second consequence will be the need for a substantial and rapid adaptation of the health care system. Three selected aspects are addressed below: 1) the increase of resources, 2) the improvement of performance, and 3) the reduction of demand through preventive strategies.

Key Words

Aging epidemiologic transition human resources performance of systems of care preventive strategies systems of care 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Paccaud F, Sidoti Pinto C, Marazzi A, Mili J. Age at death and rectangularisation of the survival curve: trends in Switzerland, 1969–1994. J Epidemiol Community Health 1998; 52: 412–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Omran AR. The epidemiologic transition: A theory of the epidemiology of population change. Milbank Memorial Fund Quarterly 1971; 49: 509–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Bovet P, Shamlaye H, Paccaud F. Epidemiology and prevention of cardiovascular disease in the Seychelles islands (Indian Ocean). CVD Prevention 1999; 2: 261–72.Google Scholar
  4. 4.
    Cooper R, Rotimi C, Ataman S, et al. The prevalence of hypertension in seven populations of West African origin. Am J Public Health 1997; 87: 160–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Larkin M. Centenarians point the way to healthy ageing. Lancet 1999; 353: 1074.PubMedCrossRefGoogle Scholar
  6. 6.
    Paccaud F. Bisig B. Evolution récente de la mortalité des personnes âgées en Suisse. Méd Hyg 1989; 47: 3478–82.Google Scholar
  7. 7.
    Murphy M. Charlton J. Eds. Health of adults. Britain 1841–94. Vol. 2. London: Office of National Statistics, 1997.Google Scholar
  8. 8.
    Hausser D, Jeangros C, Martin J. La consultation médicale: Étude de la pratique ambulatoire en Suisse romande. Genève: Méd et Hyg, 1990.Google Scholar
  9. 9.
    Silver G. The feminisation of medical practice. Lancet 1990; 335: 1149–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Chesnais JC. Le crépuscule de l’Occident: démographie et politique. Paris: Laffont, 1995.Google Scholar
  11. 11.
    Bureau international du travail. Migrants, réfugiés et coopération internationale. Genève: BIT, 1994.Google Scholar
  12. 12.
    Smith D. State of the world. London: Penguin Books, 1999.Google Scholar
  13. 13.
    Kindig DA, Libby DL. Domestic production vs international immigration: Options for the US physician workforce. JAMA 1996; 276: 978–82.PubMedCrossRefGoogle Scholar
  14. 14.
    Price D, Pollock AM, Shaoul J. How the World Trade Organization is shaping domestic policies in health care. Lancet 1999; 354: 1889–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Stocker K. Waitzkin H. Iriart C. The exportation of managed care to Latin America. N Engl J Med 1999; 340: 1131–36.Google Scholar
  16. 16.
    Smith R. Global competition in health care. BMJ 1996; 313: 764–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Leidl R. How will the single European market affect health care? BMJ 1991; 303: 1081–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Miller RH, Luft HS. Estimating health expenditure growth under managed competition. JAMA 1995; 273: 656–62.PubMedCrossRefGoogle Scholar
  19. 19.
    Relman AS. The health care industry: where is it taking us? N Engl J Med 1991; 325: 854.PubMedCrossRefGoogle Scholar
  20. 20.
    The NHS Performance Assessment Framework. National Health Service, 1999.Google Scholar
  21. 21.
    World Health Report 2000. Health systems: improving performance. Geneva: WHO, 2000.Google Scholar
  22. 22.
    Cochrane A. Effectiveness and efficiency. London: Nuffield Provincial Hospital Trust, 1972.Google Scholar
  23. 23.
    McKeown T. The role of medicine: Dream, mirage or nemesis? London: Nuffield Provincial Hospital Trust, 1976.Google Scholar
  24. 24.
    Tunstall-Pedoe H, Vanuzzo D, Hobbs M. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000; 355: 688–700.PubMedCrossRefGoogle Scholar
  25. 25.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31.000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71–85.Google Scholar
  26. 26.
    Paccaud F Holly A. Technological change in treatment of myocardial infarction in Switzerland, 1985–1993. In McClellan M, Kessler D, Eds. A global analysis of technological change in health care: heart attacks. Ann Arbor: Michigan University Press. 2002.Google Scholar
  27. 27.
    Robine JM, Mormiche P, Cambois E. Evolution des courbes de survie totale, sans maladie chronique et sans incapacité en France de 1981 à 1991: application d’un modèle de l’OMS. Annales de démographie historique (Paris) 1996: 99–115.Google Scholar
  28. 28.
    Grueneberg EM. The failure of success. Milbank Q 1977; 55: 3–24.Google Scholar
  29. 29.
    Lentzner HR. Pamuk ER. Rhodenhiser EP. et al. The quality of life in the year before death. Am J Public Health 1992; 82: 1093–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Nusselder WJ, Van der Velden K, Van Sonsbeek JLA, et al. The elimination of selected chronic diseases in a population: the compression and expansion of morbidity. Am J Public Health 1996; 86: 187–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Lubitz J. Beebe J. Baker C. Longevity and Medicare expenditures. N Engl J Med 1995; 332: 999–1003.CrossRefGoogle Scholar
  32. 32.
    Fries JF. Aging, natural death and the compression of morbidity. N Engl J Med 1980; 303: 130–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Grueneberg EM. The failure of success. Milbank Q 1977; 55: 3–24.Google Scholar
  34. 34.
    Vita AJ. Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability. N Engl J Med 1998; 338: 1035–41.Google Scholar
  35. 35.
    Terry MB. Susser E. The impact of fetal and infant exposures along the life course. Int J Epidemiol 2001; 30: 15–23.Google Scholar
  36. 36.
    Kramer MS. Association between restricted fetal growth and adult chronic disease: Is it causal? Is it important? Am J Epidemiol 2000; 152: 605–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Lucas A, Fewtrell MS, Cole TJ. Fetal origins of adult disease — The hypothesis revisited. BMJ 1999; 319: 245–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Nigel P, Mervyn S. Early origin of coronary heart disease. BMJ 1995; 310: 311–2.Google Scholar
  39. 39.
    Fall CH, Osmond C, Barker DJ, et al. Fetal and infant growth and cardiovascular risk factors in women. BMJ 1995; 310: 428–32.PubMedCrossRefGoogle Scholar
  40. 40.
    Eriksson JG, Forsén T, Tuomilehto J, et al. Catch-up growth in childhood and death from coronary heart disease: Longitudinal study. BMJ 1999; 318: 427–31.PubMedCrossRefGoogle Scholar
  41. 41.
    Kuh D, Ben-Shlomo Y, Eds. A life course approach to chronic disease epidemiology. Oxford: Oxford University Press. 1997.Google Scholar

Copyright information

© Springer Internal Publishing Switzerland 2002

Authors and Affiliations

  1. 1.Institute of Social and Preventive MedicineFaculty of Medicine of Lausanne and Cantonal HospicesLausanneSwitzerland

Personalised recommendations